Vosevi is intended as a follow-up treatment for adults with chronic hepatitis C virus genotypes 1 through 6 who have mild or no cirrhosis.
The fixed-dose combination tablet combines Gilead’s two previously approved hepatitis C treatments Sovaldi and Epclusa, along with a new drug, voxilaprevir.
More articles on supply chain:
Herbal coffee recalled for containing erectile dysfunction drug ingredien
Puma Biotech earns FDA approval for breast cancer drug
A supply chain expert on what your performance dashboard is missing
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
